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Abstract 
Easy preparation of chimeric nanobodies with various scaffolds is important for customizing abilities of nanobodies 
toward practical utilization. To accomplish high-throughput production of various nanobodies, utilization of microbes 
is an attractive option. In the present study, various chimeric nanobodies were prepared using the methylotrophic 
yeast Pichia pastoris. We designed chimeric nanobodies with complementarity-determining regions (CDRs) against 
green fluorescent protein (GFP) or cluster of differentiation 4 (CD4) based on the scaffold of GFP-nanobody. FLAG-
tagged chimeric nanobodies were prepared by one-step cloning and produced using P. pastoris. Secreted chimeric 
nanobodies were purified from the culture media of P. pastoris transformants. Relative binding abilities of purified 
chimeric nanobodies to GFP and CD4 was tested using a BIACORE T-200. P. pastoris successfully produced a high yield 
of FLAG-tagged chimeric nanobodies. FLAG-tagged GFP- and CD4-nanobodies were shown to specifically bind to 
GFP and CD4, respectively. Chimeric nanobodies, in which the CDR2 or 3 of GFP-nanobody was replaced with CDRs 
of CD4-nanobody, acquired the ability to bind to CD4 without binding to GFP. These results demonstrate successful 
production of functional chimeric nanobodies using P. pastoris. These results also suggest that swapping of CDRs, 
especially CDRs 2 or 3, potentially enables a novel method of creating nanobodies.
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Introduction
The heavy chain domains of Camelidae sp. antibod-
ies (Hamers-Casterman et  al. 1993), or nanobodies, are 
increasingly attracting attention for their small size and 
ability to bind specifically to targets. The practical appli-
cations of nanobodies range from capturing certain 
molecules (Beghein and Gettemans 2017) to deliver-
ing molecules to targets in vivo (Hu et al. 2017), offering 
attractive tools for diagnostics (De Meyer et al. 2014; Hu 
et al. 2017) and therapeutics (Bannas et al. 2017; Hu et al. 
2017). Nanobodies are also used in in  vitro molecular 
studies, for example for isolating proteins and protein-
associated molecules (Bannas et al. 2017).
Being single-domain antibodies, nanobodies are eas-
ily produced by in vitro methods (McMahon et al. 2018) 
or by various host cells including bacteriophages (Arbabi 
Ghahroudi et  al. 1997; Pardon et  al. 2014), Escherichia 
coli (Conrath et al. 2001; Pardon et al. 2014), yeast cells 
such as Aspergillus sp. (Joosten et al. 2005; Okazaki et al. 
2012), Saccharomyces cerevisiae (Gorlani et al. 2012), and 
Pichia pastoris (Ezzine et al. 2012), in addition to mam-
malian cells (Agrawal et  al. 2012; Zhang et  al. 2009). 
According to comparison of different methods for pro-
ducing nanobodies by Frenzel and De Meyer, optimized 
yield of nanobodies is generally similar among Gram-
negative microbes, yeast cells, and mammalian cells 
(Frenzel et  al. 2013; De Meyer et  al. 2014). Mammalian 
production benefits that the produced nanobodies can 
have mammalian post-translational modifications (Palo-
mares et al. 2004). Microbial production of recombinant 
proteins is easier to test (Ferrer-Miralles and Villaverde 
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2013), and has been used for high-throughput screening 
of protein libraries (Boder and Wittrup 1997). Recently, 
yeast cells including the methylotrophic yeast P. pastoris 
have attracted increased attention as a host for nanobody 
production (Baghban et al. 2016; Pourasadi et al. 2017). In 
addition to being a microbe which allows high-through-
put production, P. pastoris enables secretory production 
of recombinant proteins thorough folding control system 
of eukaryotic cells (Cereghino et al. 2002).
Various synthetic nanobodies have been reported 
through screening of nanobodies having random 
sequences. Phage display and cell surface display system 
enabled genotype–phenotype linking of nanobody librar-
ies and thus enabled production and screening of large 
number of nanobodies (Galan et al. 2016; McMahon et al. 
2018; Yan et al. 2014). Gu and colleagues reported in vitro 
production of DNA-barcoded nanobody library (Gu et al. 
2014). In the method, random nanobody sequences are 
fused with random DNA barcodes and can be identi-
fied through concentration of barcodes with functional 
molecules followed by next-generation sequencing 
(NGS) analysis (Gu et al. 2014). Recently, production of 
peptide-barcoded nanobodies using microbial hosts has 
been reported, in which random nanobody sequences are 
fused with random peptide barcodes and can be identi-
fied by LC–MS/MS and NGS analysis (Egloff et al. 2019; 
Miyamoto et  al. 2019). Egloff and colleagues prepared 
library of randomized nanobody sequences fused with 
peptide library produced by E. coli (Egloff et al. 2019). We 
reported secretory production of peptide-barcoded nan-
obodies using P. pastoris (Miyamoto et  al. 2019). Since 
peptide-barcodes are smaller compared to nanobody 
itself, they have a little effect on binding abilities of nano-
bodies compared to conventional FLAG-tag composed 
by eight amino acids (Miyamoto et al. 2019).
Although a number of studies aim at “random” screen-
ing of nanobodies, practically it is important to select 
amino acids or amino acid regions to be mutated, for 
library preparation. Ribosome and phage display meth-
ods enable screening of up to  107–1012 library size (Zim-
mermann et  al. 2018), which allow limited number of 
amino acid residues to be changed. Nanobody has three 
variable regions called complementarity-determining 
regions (CDRs). Previously, Deschaght and colleagues 
showed that there are large varieties in amino acid 
sequence of CDRs compared to other region, via NGS 
analysis of 28 nanobodies (Deschaght et al. 2017). So far, 
CDR has been used to prepare protein libraries in vari-
ous hosts including yeast cells (McMahon et al. 2018) or 
phage (Yan et  al. 2014) in addition to in  vitro methods 
including ribosome display (Zimmermann et  al. 2018). 
Of three CDRs of nanobodies, it has been suggested that, 
in some nanobodies, CDR3 is largely responsible for 
specific binding to substrates (Gray et  al. 2017), which 
has been used as a target for randomization when pre-
paring nanobody libraries (Zimmermann et  al. 2018; 
Moutel et al. 2016).
In practical nanobody applications, CDRs are inserted 
into proper scaffolds, such as universally humanized scaf-
folds (Vincke et al. 2009; Moutel et al. 2016) or scaffolds 
suitable for tissue imaging (De Groeve et al. 2010), with 
some integrated mutations to retain binding abilities 
(Rahbarizadeh et al. 2011). While CDR domain swapping 
can decrease the binding ability of nanobodies (Hwang 
and Foote 2005; Rahbarizadeh et al. 2011), utilization of 
scaffolds with specific properties is an attractive option 
for improving or preparing functional proteins. The 
amino acid sequence of the scaffold is highly conserved 
across nanobodies (Conrath et  al. 2001; Saerens et  al. 
2005; Deschaght et al. 2017), which means that only small 
number of residues need to be modified.
In the present study, we used P. pastoris cells for the 
production of chimeric nanobodies to test the possi-
bility of CDR swapping. We utilized green fluorescent 
protein (GFP)-nanobody (Rothbauer et  al. 2006) and 
cluster of differentiation 4 (CD4)-nanobody (Roobrouck 
and Stortelers 2015) as models for preparing chimeric 
nanobodies. GFP-nanobody is one of the most popu-
lar nanobodies with the crystal structure of which has 
been analyzed (Kubala et al. 2010). CD4 is a cell surface 
antigen of mammalian immune cells that can be used 
as a marker for predicting clinical outcome in colorec-
tal tumor (Galon et  al. 2006). Unlike GFP-nanobody, 
the crystal structure of CD4-nanobody has not yet been 
resolved. Here we demonstrate methods for easy produc-
tion of chimeric nanobodies in P. pastoris cells by utiliz-
ing seamless cloning. We also tested the production of 
chimeric nanobodies tagged with long peptide sequences 
for easy purification and detection of nanobodies.
Materials and methods
Strains and media
Cells and media were prepared according to the 
previous report (Aoki et  al. 2011). E. coli strain 
DH5α  [F−,  Φ80d  lacZΔM15, Δ(lacZYA–argF)U169, 
deoR,  recA1, endA1, hsdR17(rK–  mK+), phoA, supE44, 
λ–,  thi–1, gyrA96, relA1] (Toyobo, Osaka, Japan) was 
used as a host for plasmid construction. P. pastoris 
(Komagataella phaffii) strain GS115 [his4] was pur-
chased from Thermo Fisher Scientific (Rockford, IL). 
E. coli cells transformed with plasmids were grown 
on lysogeny broth  (LB) medium [0.5% (w/v) yeast 
extract, 1% (w/v) Bacto Tryptone, 1% (w/v) NaCl] con-
taining 100  μg/mL ampicillin. After transformation 
with plasmids, P. pastoris cells were grown on mini-
mal dextrose (MD) agar plate containing 1.34% (w/v) 
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yeast nitrogen base w/o a.a., 2% (w/v) glucose, and 2% 
(w/v) agar. Obtained P. pastoris colonies were precul-
tured in buffered glycerol complex (BMGY) medium 
containing 1% (w/v) yeast extract, 2% (w/v) peptone, 
100 mM  KPO4 pH 6.0, 2.68% (w/v) yeast nitrogen base 
w/o a.a., and 0.2% 500× biotin. After preculture, cells 
were grown in a buffered methanol complex (BMMY) 
medium (expression medium) containing 1% (w/v) 
yeast extract, 2% (w/v) peptone, 100  mM  KPO4 pH 
6.0, 2.68% (w/v) yeast nitrogen base w/o a.a., 0. 2% 
500× biotin, and 0.5% (v/v) methanol.
Plasmid construction and transformation
All primers used in this study are listed in Additional 
file  1: Table  S1. Nucleotide sequences encoding GFP-
nanobody (Rothbauer et  al. 2006) and CD4-nanobody 
(Roobrouck and Stortelers 2015) genes were optimized 
for expression in P. pastoris, as shown in Additional 
file  1: Table  S2, and were purchased from Integrated 
DNA Technologies, Inc (Coralville, IA). Chimeric 
nanobodies were constructed as shown in Fig. 1. Both 
nucleotide sequences for GFP-nanobody and CD4-
nanobody were submitted to the DDBJ Sequenced 
a
CDRs of


























GFP Nanobody    QVQLVESGGALVQPGGSLRLSCAASGFPVNRYSMRWYRQAPGKEREWVA
CD4 Nanobody EVQLVESGGGSVQPGGSLTLSCGTSGRTFN--VMGWFRQAPGKEREFVA
:********. ******* ***.:** ..*   * *:*********:**
GFP Nanobody GMSSAGD---RSSYEDSVKGRFTISRDDARNTVYLQMNSLKPEDTAVYY
CD4 Nanobody AVRWSSTGIYYTQYADSVKSRFTISRDNAKNTVYLEMNSLKPEDTAVYY    
.:  :.     :.* ****.*******:*:*****:*************
GFP Nanobody CNVN---------VGFEYWGQGTQVTVSS
CD4 Nanobody CAADTYNSNPARWDGYDFRGQGTQVTVSS





Fig. 1 Chimeric nanobodies prepared in the present study. a Construction of chimeric nanobodies. Peptide tags were fused to the C-terminus of 
nanobodies. b Simple illustration of a nanobody used for swapping. c Name and construction of chimeric nanobodies. Long white block: nanobody 
scaffolds with amino acid sequences derived from GFP-nanobody, long black block: nanobody scaffolds with amino acid sequences derived 
from CD4-nanobody, small white block: CDRs with amino acid sequences derived from GFP-nanobody, small black block: CDRs with amino acid 
sequences derived from CD4-nanobody, cCD4 CDRX: chimeric nanobody with CDRX of GFP-nanobody replaced with that of CD4-nanobody, CD4N: 
CD4 -nanobody with peptide tags containing two FLAG-tag sequences (see also Additional file 1: Table S3), GFPN: GFP-nanobody with peptide tags 
containing two FLAG-tag sequences (see also Additional file 1: Table S3). d Amino acid sequence alignment of GFP- and CD4-nanobodies prepared 
by CLUSTALW (Larkin et al. 2007). Asterisks indicate identical amino acids. Colons indicate similar amino acids. Dots indicate almost similar amino 
acids. Blanks indicate non-homologous amino acids
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Read Archive with accession numbers LC472971 and 
LC472972, respectively. Nucleotide fragments were 
amplified by KOD plus Neo DNA polymerase (Toy-
obo, Osaka, Japan). DNA fragments were integrated 
into a pPIK9K vector (Invitrogen) using an In-Fusion 
HD Cloning Kit (Takara Bio, Otsu, Japan) to produce 
recombinant proteins with the amino acid sequences 
shown in Additional file 1: Table S3. For each nanobody, 
long peptide tags containing two FLAG-tag coding 
sequences were added to the C-terminus for easy han-
dling of nanobodies (Fig. 1a). Figure 2 shows the types 
of nucleotide fragments prepared for the construction 
of each chimeric nanobody. Nucleotide sequence of 
the plasmids were determined by Sanger sequencing 
(Eurofins Genomics, Tokyo, Japan). The plasmids were 
digested with SacI (Toyobo) and transformed to P. pas-
toris cells using Frozen EZ Yeast Transformation II Kit 
(Zymo Research, Irvine, CA), following manufacturer’s 
instructions. 
Protein production and purification
Secreted recombinant proteins were purified with minor 
modifications to previously reported methods (Aoki 
et al. 2011; Miyamoto et al. 2019). To produce nanobod-
ies, P. pastoris colonies on MD agar plate were cultured 
in 20 mL of BMGY medium with shake at 250 rpm, 48 h 
at 30  °C. The cells were cultured in 15  mL of BMMY 
medium for 24 h at 30 °C with shake at 250 rpm. Produc-
tion of recombinant proteins were checked by using 10 
μL of culture supernatants for SDS-PAGE as described in 
the next section. Cell culture was transferred to a 50 mL 
tube and centrifuged at 8000×g for 60 min at 4 °C. Cul-
ture supernatants (15  mL) obtained after centrifugation 
were filtrated with 0.22  μm filter and concentrated in a 
Amicon Ultra-15 Centrifugal Filters Ultracel-10K (Milli-
pore, Billerica, MA). The samples were washed with TBS 
buffer (Nacalai, Kyoto, Japan) twice and resuspended in 
TBS buffer. The obtained sample solution (5 mL) contain-































Fig. 2 Overview of plasmid construction schemes for production of chimeric nanobodies. a Overview of the composition of chimeric nanobodies. 
Nanobodies with CDR1, 2, and 3 were inserted into single plasmids. b Scheme for preparing each chimera. Cross: positions of homologous 
recombination
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250 μL of anti-FLAG M2 affinity gel (Sigma, Saint Louis, 
MO) using disposable columns, following manufacturer’s 
instructions. Proteins were eluted from the affinity gel 
using 1 mL of 0.1 M glycine–HCl (pH 3.5) and immedi-
ately neutralized by mixing with 20 μL of 1 M Tris (pH 
8.0). The protein solution was added to Amicon Ultracel-
3K (Millipore) and the buffer was replaced three times 
with 500 μL of PBS. The obtained protein solution was 
kept at 4 °C until use. The final protein concentration in 
the samples was determined by SDS-PAGE as described 
below.
SDS‑PAGE
Culture supernatants, purified proteins, or a serial dilu-
tion of bovine serum albumin (BSA) (225, 450, 900, 1125, 
and 2250 ng per lane) were loaded into e-PAGEL 5–20% 
(Atto, Tokyo, Japan) and stained with CBB Stain One 
Super (Nacalai) according to the manufacturer’s instruc-
tions. Gel images were obtained using the ImageQuant 
LAS 4000 minisystem (GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden) and analyzed with ImageJ software 
(Abramoff et  al. 2004). The protein concentration was 
quantified by applying the band intensity to a standard 
curve generated from the analysis of protein bands pre-
pared using BSA.
Obtaining binding abilities of nanobodies by surface 
plasmon resonance
Recombinant GFP (ProSpec, Ness-Ziona, Israel) or CD4 
(R&D Systems, MN, USA) were immobilized on a Sensor 
Chip CM5 (GE Healthcare) using an Amine Coupling Kit 
(GE Healthcare) according to the manufacturer’s instruc-
tions for the BIACORE-T200 instrument (GE Health-
care). CD4 (20 μg/mL, pH 6.0) and GFP (20 μg/mL, pH 
5.0) solutions were prepared using 10 mM HEPES buffer 
(GE Healthcare) or 10  mM acetate buffer (GE Health-
care), respectively. CD4 or GFP were immobilized on 
CM5 by an automatic program according to the manufac-
turer’s instructions at 25 °C with a flow rate of 10 μL/min. 
The binding of nanobodies to CD4 or GFP was tested at 
25  °C according to the manufacturer’s instructions for 
the BIACORE-T200 instrument using HBS-EP buffer 
(0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, and 
0.005% (w/v) Surfactant P20) as a running buffer. Nano-
bodies were prepared to a concentration of 0.4 μM using 
HBS-EP buffer. Binding to CD4 and GFP was analyzed 
under the following conditions: contact time 180 s, flow 
rate 30 μL/min, and dissociation time 180 s. Sensor chips 
were recovered by 10 mM NaOH with a contact time of 
30 s and a flow rate of 30 μL/min. Response units of CD4- 
or GFP-nanobodies (CD4 N and GFP N, respectively) to 
CD4 or GFP, respectively, were used as positive controls. 
All the data obtained were analyzed by Biacore T200 
Evaluation Software (GE Healthcare) and the binding lev-
els (increase of relative response from the base line) were 
obtained. The data were adjusted as follows. For test-
ing binding abilities of nanobodies to CD4, the relative 
binding level of CD4 N was set to 1. For testing binding 
abilities of nanobodies to GFP, the relative binding level 
of GFP N was set to 1. Statistical significance was evalu-
ated using the unpaired Student’s t test for comparisons 
between two means. For all experiments, significance 
was established at p ≤ 0.05.
Results
Production of recombinant nanobodies by P. pastoris
Chimeric nanobodies (Fig.  1) were successfully con-
structed by one-step cloning of 1–4 nucleotide fragments 
(Fig.  2). Recombinant proteins in 10 μL P. pastoris cul-
ture supernatant showed clear single bands (Fig. 3). The 
molecular masses of each band ranged from 14 to 17 kDa, 
representing the molecular weight of the products.
Relative binding abilities of chimeric nanobodies to CD4
CD4 and GFP were immobilized onto a CM5 chip at 
9695.5 response unit (RU) and 1189.8 RU, respectively. 
Both nanobodies showed specific binding to their origi-
nal targets (CD4 and GFP, respectively). CD4- and GFP-
nanobodies did not respond to non-target molecules 
(GFP and CD4, respectively) (data not shown). To test 
the effect of CDR swapping on the ability of the nano-
bodies to bind to novel targets, relative binding abili-
ties of chimeric nanobodies to CD4 was investigated 
(Fig.  4a and Additional file  1: Table  S4). The response 
of GFP-nanobody (GFP N) to CD4 [0.025 ± 0.029 when 
response of CD4-nanobody (CD4N) to CD4 was set 







Fig. 3 Chimeric nanobodies detected in the culture supernatants 
of P. pastoris transformants. Culture supernatants of transformants 
(10 μL for each) were loaded. GFP N and CD4 N represents GFP- or 
CD4-nanobodies, respectively, tagged with long peptide tags 
containing two FLAG-tags
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CD4-nanobody. There were no significant changes 
when the CDR1 of GFP-nanobody was replaced 
with that of CD4-nanobody (0.037 ± 0.020). On the 
other hand, when the CDR2 (0.091 ± 0.011) or CDR3 
(0.10 ± 0.011) of GFP-nanobody was replaced with that 
of CD4, the chimeric nanobodies showed a significant 
increase in relative binding response to CD4 com-
pared to the original GFP-nanobody. There were no 
significant differences in response to CD4 among the 
chimeric nanobodies in which CDR2 or 3 is replaced, 
suggesting the importance of CDR2 and 3 in CD4 bind-
ing. Chimeric nanobodies in which all CDRs had been 
replaced showed approximately 10% response to CD4-
nanobody (0.096 ± 0.011).
Relative binding abilities of chimeric nanobodies to GFP
To test the effect of CDR swapping of original bind-
ing targets, the binding abilities of chimeric nanobod-
ies to GFP was investigated (Fig.  4b). The response of 
CD4-nanobody to GFP [0.065 ± 0.028 when response of 
GFP-nanobody (GFP N) to GFP was set to 1]was approxi-
mately 15 times lower than that of GFP-nanobody. When 
the CDR1 of GFP-nanobody was replaced with that of 
CD4, the relative binding response to GFP dropped by 
80% (0.22 ± 0.029), although this was still a significantly 
higher response than with the CD4-nanobody. When 
the CDR3 of GFP-nanobody was replaced with that of 
CD4-nanobody, the relative binding response to GFP 
(0.039 ± 0.026) was similar to that of CD4-nanobody 
(0.065 ± 0.028), suggesting that the replacement of CDR3 
results in loss of the ability to bind to GFP.
Discussion
The present study demonstrated a simple and easy way 
of producing chimeric nanobodies in P. pastoris using 
one-step cloning of up to four nucleotide fragments. 
Since primer sequences used for preparing CDR and 
scaffold fragments are easily randomized or mutated, this 
method could be useful in producing large-scale libraries 
of chimeric nanobodies for high-throughput screening, 
including screening methods utilizing peptide-barcode 
(Egloff et  al. 2019; Miyamoto et  al. 2019). Notably, this 
method can be also used together with other synthetic 
methods for nanobody preparation (Moutel et al. 2016), 
which would enable easy preparation of nanobodies 
with variety of CDR length. In the chimeric nanobod-
ies produced in the present study, replacement of CDRs 
significantly altered the response of nanobodies to both 
GFP and CD4, as expected. Replacement of the scaffold 
caused a decrease in the binding ability of nanobod-
ies to targets, which is comparable to previous reports 
(Hwang and Foote 2005; Rahbarizadeh et al. 2011; Zabe-
takis et al. 2013). Scaffolds of GFP- and CD4-nanobodies 
have seven similar, three almost similar, and three non-
homologous amino acid residues (Fig.  1d), suggesting 
that the decreased response to substrates is dependent 
on these amino acid residues. Unexpectedly, we did not 
detect significant synergistic increase in relative binding 
abilities among CDRs of CD4 nanobody on the scaffold 
of GFP nanobody. It is possible that synergistic effect 
of CDRs do not always happen; it has been previously 
reported by Zabetakis and colleagues that that synergistic 
increase in thermostability did not occur when CDRs of 
nanobody against the toxin Staphylococcal enterotoxin B 



























































































Fig. 4 Relative binding abilities of chimeric nanobodies to CD4 
(a) and GFP (b). See also Fig. 1c for details of the illustration. 
Long block: nanobody scaffolds, small block: CDRs, white block: 
amino acid sequences derived from GFP-nanobody, black block: 
amino acid sequences derived from CD4-nanobody. a Relative 
response of chimeric nanobodies to CD4 compared to the 
response of CD4-nanobody. See also Additional file 1: Table S4 
for the binding level in each experiment before normalization. b 
Relative response of chimeric nanobodies to GFP compared to the 
response of GFP-nanobody. See also Additional file 1: Table S5 for 
the binding level in each experiment before normalization. N = 3, 
bar = mean ± SD, **p < 0.01, *p < 0.05
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Further investigation is needed to determine how the 
specific CDRs and scaffolds synergistically or non-syner-
gistically affect binding abilities of nanobody with respect 
to polypeptide length and diverse sequences. Neverthe-
less, this study demonstrated design and high-through-
put production of various chimeric nanobodies using P. 
pastoris. Future studies will focus on randomization of 
CDRs in addition to three non-homologous amino acid 
residues on scaffolds to obtain novel and highly specific 
nanobodies via high-throughput screening.
Additional file
Additional file 1. Additional tables.
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